NOUVEAUX DERIVES DE L'INDOLE, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE KDR

2-(Pyrazolyl or indazolyl)-indole derivatives (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. 2-(pyrazolyl or indazolyl)-indole derivatives of formula (I), in all possible racemic, enantiomeric or diasteroi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BOUCHARD HERVE, UGOLINI ANTONIO
Format: Patent
Sprache:fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BOUCHARD HERVE
UGOLINI ANTONIO
description 2-(Pyrazolyl or indazolyl)-indole derivatives (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. 2-(pyrazolyl or indazolyl)-indole derivatives of formula (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. [Image] R 1>pyrazolyl or indazolyl, optionally substituted by one or more of halo, hydroxy, nitro, cyano, R 4>, OR4, SR 4>, COR 4>, OCOR 4>, COOR 4>, COOH (optionally as salt), NR 5>COR 4>, NR 5>COOR 4>, S(O) nR 4>, S(O) nOR 4>, NR5-SO 2R 4>, OS(O) nR 4>, NY 1>Y 2>, CONY 1>Y 2>, OCONY 1>Y 2>, NR5CONY 1>Y 2>, S(O) nNY 1>Y 2>or optionally substituted thienyl; R 2>, R 3>hydrogen, halo, hydroxy, nitro, cyano, R 4>, OR 4>, COR 4>, OCOR 4>, COOR 4>, COOH, NR 5>COR 4>, NR5COOR 4>, S(O) nR 4>, S(O) nOR 4>, NR 5>-SO 2R 4>, NY 1>Y 2>, CONY 1>Y 2>, NR 5>CONY 1>Y 2>, S(O) nNY 1>Y 2>or OCONY 1>Y 2>; or R 2>+ R 3>optionally substituted 4-6 membered ring optionally containing one or more heteroatoms O,N or S; n : 0-2; R 4>alkyl, alk-NY 1>Y 2>, alk-CONY 1>Y 2>, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, (hetero)cycloalkylalkyl, heteroarylalkyl or aralkyl, all optionally substituted; R 5>hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, (hetero)aryl, aralkyl, (hetero)cycloalkylalkyl, or heteroarylalkyl, all optionally substituted; Y 1>, Y 2>hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, heterocycloalkylalkyl, (hetero)aryl, (hetero)aralkyl or (hetero)arylcarboxy, (all optionally substituted by one or more of halo, hydroxy, alkoxy, alkyl (optionally substituted by hydroxy or carboxy), cyano, nitro, trifluoromethyl, trifluoromethoxy, carboxy (optionally as salt or optionally substituted alkyl ester), Nalk-CO-alk, NHCO-alk, S(O) n-alk, NHS(O) n-alkyl, NHCO-NY 3>Y 4>, CONY 3>Y 4>, S(O) nNY 3>Y 4>, aryl, arylalkoxy, aryloxy, aryloxyalkyl, heteroaryl or heterocycloalkyl (both optionally substituted by one or more T 1>)); or NY 1>Y 2>optionally substituted ring; Y 3>, Y 4>hydrogen, aryl or alkyl (optionally substituted by one or more T 1>); T 1>halo, alkyl, carboxy (optionally as salt or ester) or amino (optionally substituted by 1 or 2 alkyl or by one phenyl (optionally substituted by a dioxol residue)); and alk : 1-6C alkyl. ACTIVITY : Cytostatic; Antiallergic; Antiasthmatic; Anticoagulant; Thrombolytic; Ophthalmological; Antipsoriatic; Antiasthmatic; Antirheumatic; Antidiabetic; Antiarteriosclerotic; A
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_FR2854159B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>FR2854159B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_FR2854159B13</originalsourceid><addsrcrecordid>eNqNzbEOgjAUhWEWB6O-w91ccEAl0bHQS7iRtlhuiRshpk5GSfAlfGup8QGc_uXLOfPorY1rUbgLSLTUYjMVqjVpaSqMoUJnobZYCyuYjAYBTGwxKIWScqFQcxNDblRtGgqmgboUVokcHdPZTZPIoA0LFWyQCoF0SRnxNP99PEm7jGa3_j761a-LCArkvNz44dn5ceiv_uFfXWG3h3SfpMcs2f1BPhvdPl4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOUVEAUX DERIVES DE L'INDOLE, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE KDR</title><source>esp@cenet</source><creator>BOUCHARD HERVE ; UGOLINI ANTONIO</creator><creatorcontrib>BOUCHARD HERVE ; UGOLINI ANTONIO</creatorcontrib><description>2-(Pyrazolyl or indazolyl)-indole derivatives (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. 2-(pyrazolyl or indazolyl)-indole derivatives of formula (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. [Image] R 1&gt;pyrazolyl or indazolyl, optionally substituted by one or more of halo, hydroxy, nitro, cyano, R 4&gt;, OR4, SR 4&gt;, COR 4&gt;, OCOR 4&gt;, COOR 4&gt;, COOH (optionally as salt), NR 5&gt;COR 4&gt;, NR 5&gt;COOR 4&gt;, S(O) nR 4&gt;, S(O) nOR 4&gt;, NR5-SO 2R 4&gt;, OS(O) nR 4&gt;, NY 1&gt;Y 2&gt;, CONY 1&gt;Y 2&gt;, OCONY 1&gt;Y 2&gt;, NR5CONY 1&gt;Y 2&gt;, S(O) nNY 1&gt;Y 2&gt;or optionally substituted thienyl; R 2&gt;, R 3&gt;hydrogen, halo, hydroxy, nitro, cyano, R 4&gt;, OR 4&gt;, COR 4&gt;, OCOR 4&gt;, COOR 4&gt;, COOH, NR 5&gt;COR 4&gt;, NR5COOR 4&gt;, S(O) nR 4&gt;, S(O) nOR 4&gt;, NR 5&gt;-SO 2R 4&gt;, NY 1&gt;Y 2&gt;, CONY 1&gt;Y 2&gt;, NR 5&gt;CONY 1&gt;Y 2&gt;, S(O) nNY 1&gt;Y 2&gt;or OCONY 1&gt;Y 2&gt;; or R 2&gt;+ R 3&gt;optionally substituted 4-6 membered ring optionally containing one or more heteroatoms O,N or S; n : 0-2; R 4&gt;alkyl, alk-NY 1&gt;Y 2&gt;, alk-CONY 1&gt;Y 2&gt;, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, (hetero)cycloalkylalkyl, heteroarylalkyl or aralkyl, all optionally substituted; R 5&gt;hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, (hetero)aryl, aralkyl, (hetero)cycloalkylalkyl, or heteroarylalkyl, all optionally substituted; Y 1&gt;, Y 2&gt;hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, heterocycloalkylalkyl, (hetero)aryl, (hetero)aralkyl or (hetero)arylcarboxy, (all optionally substituted by one or more of halo, hydroxy, alkoxy, alkyl (optionally substituted by hydroxy or carboxy), cyano, nitro, trifluoromethyl, trifluoromethoxy, carboxy (optionally as salt or optionally substituted alkyl ester), Nalk-CO-alk, NHCO-alk, S(O) n-alk, NHS(O) n-alkyl, NHCO-NY 3&gt;Y 4&gt;, CONY 3&gt;Y 4&gt;, S(O) nNY 3&gt;Y 4&gt;, aryl, arylalkoxy, aryloxy, aryloxyalkyl, heteroaryl or heterocycloalkyl (both optionally substituted by one or more T 1&gt;)); or NY 1&gt;Y 2&gt;optionally substituted ring; Y 3&gt;, Y 4&gt;hydrogen, aryl or alkyl (optionally substituted by one or more T 1&gt;); T 1&gt;halo, alkyl, carboxy (optionally as salt or ester) or amino (optionally substituted by 1 or 2 alkyl or by one phenyl (optionally substituted by a dioxol residue)); and alk : 1-6C alkyl. ACTIVITY : Cytostatic; Antiallergic; Antiasthmatic; Anticoagulant; Thrombolytic; Ophthalmological; Antipsoriatic; Antiasthmatic; Antirheumatic; Antidiabetic; Antiarteriosclerotic; Anorectic; Antiparkinsonian; Antidepressant; Neuroleptic; Nootropic; Neuroprotective; Analgesic; Immunomodulator; Antiangiogenic; Vulnerary; Osteopathic. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibition of protein kinases, particularly vascular endothelial growth factor receptor 2 (KDR) and focal adhesion kinase (FAK), and insulin-like growth factor 1 receptor.</description><language>fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080111&amp;DB=EPODOC&amp;CC=FR&amp;NR=2854159B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080111&amp;DB=EPODOC&amp;CC=FR&amp;NR=2854159B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BOUCHARD HERVE</creatorcontrib><creatorcontrib>UGOLINI ANTONIO</creatorcontrib><title>NOUVEAUX DERIVES DE L'INDOLE, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE KDR</title><description>2-(Pyrazolyl or indazolyl)-indole derivatives (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. 2-(pyrazolyl or indazolyl)-indole derivatives of formula (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. [Image] R 1&gt;pyrazolyl or indazolyl, optionally substituted by one or more of halo, hydroxy, nitro, cyano, R 4&gt;, OR4, SR 4&gt;, COR 4&gt;, OCOR 4&gt;, COOR 4&gt;, COOH (optionally as salt), NR 5&gt;COR 4&gt;, NR 5&gt;COOR 4&gt;, S(O) nR 4&gt;, S(O) nOR 4&gt;, NR5-SO 2R 4&gt;, OS(O) nR 4&gt;, NY 1&gt;Y 2&gt;, CONY 1&gt;Y 2&gt;, OCONY 1&gt;Y 2&gt;, NR5CONY 1&gt;Y 2&gt;, S(O) nNY 1&gt;Y 2&gt;or optionally substituted thienyl; R 2&gt;, R 3&gt;hydrogen, halo, hydroxy, nitro, cyano, R 4&gt;, OR 4&gt;, COR 4&gt;, OCOR 4&gt;, COOR 4&gt;, COOH, NR 5&gt;COR 4&gt;, NR5COOR 4&gt;, S(O) nR 4&gt;, S(O) nOR 4&gt;, NR 5&gt;-SO 2R 4&gt;, NY 1&gt;Y 2&gt;, CONY 1&gt;Y 2&gt;, NR 5&gt;CONY 1&gt;Y 2&gt;, S(O) nNY 1&gt;Y 2&gt;or OCONY 1&gt;Y 2&gt;; or R 2&gt;+ R 3&gt;optionally substituted 4-6 membered ring optionally containing one or more heteroatoms O,N or S; n : 0-2; R 4&gt;alkyl, alk-NY 1&gt;Y 2&gt;, alk-CONY 1&gt;Y 2&gt;, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, (hetero)cycloalkylalkyl, heteroarylalkyl or aralkyl, all optionally substituted; R 5&gt;hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, (hetero)aryl, aralkyl, (hetero)cycloalkylalkyl, or heteroarylalkyl, all optionally substituted; Y 1&gt;, Y 2&gt;hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, heterocycloalkylalkyl, (hetero)aryl, (hetero)aralkyl or (hetero)arylcarboxy, (all optionally substituted by one or more of halo, hydroxy, alkoxy, alkyl (optionally substituted by hydroxy or carboxy), cyano, nitro, trifluoromethyl, trifluoromethoxy, carboxy (optionally as salt or optionally substituted alkyl ester), Nalk-CO-alk, NHCO-alk, S(O) n-alk, NHS(O) n-alkyl, NHCO-NY 3&gt;Y 4&gt;, CONY 3&gt;Y 4&gt;, S(O) nNY 3&gt;Y 4&gt;, aryl, arylalkoxy, aryloxy, aryloxyalkyl, heteroaryl or heterocycloalkyl (both optionally substituted by one or more T 1&gt;)); or NY 1&gt;Y 2&gt;optionally substituted ring; Y 3&gt;, Y 4&gt;hydrogen, aryl or alkyl (optionally substituted by one or more T 1&gt;); T 1&gt;halo, alkyl, carboxy (optionally as salt or ester) or amino (optionally substituted by 1 or 2 alkyl or by one phenyl (optionally substituted by a dioxol residue)); and alk : 1-6C alkyl. ACTIVITY : Cytostatic; Antiallergic; Antiasthmatic; Anticoagulant; Thrombolytic; Ophthalmological; Antipsoriatic; Antiasthmatic; Antirheumatic; Antidiabetic; Antiarteriosclerotic; Anorectic; Antiparkinsonian; Antidepressant; Neuroleptic; Nootropic; Neuroprotective; Analgesic; Immunomodulator; Antiangiogenic; Vulnerary; Osteopathic. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibition of protein kinases, particularly vascular endothelial growth factor receptor 2 (KDR) and focal adhesion kinase (FAK), and insulin-like growth factor 1 receptor.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzbEOgjAUhWEWB6O-w91ccEAl0bHQS7iRtlhuiRshpk5GSfAlfGup8QGc_uXLOfPorY1rUbgLSLTUYjMVqjVpaSqMoUJnobZYCyuYjAYBTGwxKIWScqFQcxNDblRtGgqmgboUVokcHdPZTZPIoA0LFWyQCoF0SRnxNP99PEm7jGa3_j761a-LCArkvNz44dn5ceiv_uFfXWG3h3SfpMcs2f1BPhvdPl4</recordid><startdate>20080111</startdate><enddate>20080111</enddate><creator>BOUCHARD HERVE</creator><creator>UGOLINI ANTONIO</creator><scope>EVB</scope></search><sort><creationdate>20080111</creationdate><title>NOUVEAUX DERIVES DE L'INDOLE, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE KDR</title><author>BOUCHARD HERVE ; UGOLINI ANTONIO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_FR2854159B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>fre</language><creationdate>2008</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BOUCHARD HERVE</creatorcontrib><creatorcontrib>UGOLINI ANTONIO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BOUCHARD HERVE</au><au>UGOLINI ANTONIO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOUVEAUX DERIVES DE L'INDOLE, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE KDR</title><date>2008-01-11</date><risdate>2008</risdate><abstract>2-(Pyrazolyl or indazolyl)-indole derivatives (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. 2-(pyrazolyl or indazolyl)-indole derivatives of formula (I), in all possible racemic, enantiomeric or diasteroisomeric forms, their addition salts with (in)organic acids or inorganic bases are new. [Image] R 1&gt;pyrazolyl or indazolyl, optionally substituted by one or more of halo, hydroxy, nitro, cyano, R 4&gt;, OR4, SR 4&gt;, COR 4&gt;, OCOR 4&gt;, COOR 4&gt;, COOH (optionally as salt), NR 5&gt;COR 4&gt;, NR 5&gt;COOR 4&gt;, S(O) nR 4&gt;, S(O) nOR 4&gt;, NR5-SO 2R 4&gt;, OS(O) nR 4&gt;, NY 1&gt;Y 2&gt;, CONY 1&gt;Y 2&gt;, OCONY 1&gt;Y 2&gt;, NR5CONY 1&gt;Y 2&gt;, S(O) nNY 1&gt;Y 2&gt;or optionally substituted thienyl; R 2&gt;, R 3&gt;hydrogen, halo, hydroxy, nitro, cyano, R 4&gt;, OR 4&gt;, COR 4&gt;, OCOR 4&gt;, COOR 4&gt;, COOH, NR 5&gt;COR 4&gt;, NR5COOR 4&gt;, S(O) nR 4&gt;, S(O) nOR 4&gt;, NR 5&gt;-SO 2R 4&gt;, NY 1&gt;Y 2&gt;, CONY 1&gt;Y 2&gt;, NR 5&gt;CONY 1&gt;Y 2&gt;, S(O) nNY 1&gt;Y 2&gt;or OCONY 1&gt;Y 2&gt;; or R 2&gt;+ R 3&gt;optionally substituted 4-6 membered ring optionally containing one or more heteroatoms O,N or S; n : 0-2; R 4&gt;alkyl, alk-NY 1&gt;Y 2&gt;, alk-CONY 1&gt;Y 2&gt;, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, (hetero)cycloalkylalkyl, heteroarylalkyl or aralkyl, all optionally substituted; R 5&gt;hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, (hetero)aryl, aralkyl, (hetero)cycloalkylalkyl, or heteroarylalkyl, all optionally substituted; Y 1&gt;, Y 2&gt;hydrogen, alkyl, alkenyl, (hetero)cycloalkyl, heterocycloalkylalkyl, (hetero)aryl, (hetero)aralkyl or (hetero)arylcarboxy, (all optionally substituted by one or more of halo, hydroxy, alkoxy, alkyl (optionally substituted by hydroxy or carboxy), cyano, nitro, trifluoromethyl, trifluoromethoxy, carboxy (optionally as salt or optionally substituted alkyl ester), Nalk-CO-alk, NHCO-alk, S(O) n-alk, NHS(O) n-alkyl, NHCO-NY 3&gt;Y 4&gt;, CONY 3&gt;Y 4&gt;, S(O) nNY 3&gt;Y 4&gt;, aryl, arylalkoxy, aryloxy, aryloxyalkyl, heteroaryl or heterocycloalkyl (both optionally substituted by one or more T 1&gt;)); or NY 1&gt;Y 2&gt;optionally substituted ring; Y 3&gt;, Y 4&gt;hydrogen, aryl or alkyl (optionally substituted by one or more T 1&gt;); T 1&gt;halo, alkyl, carboxy (optionally as salt or ester) or amino (optionally substituted by 1 or 2 alkyl or by one phenyl (optionally substituted by a dioxol residue)); and alk : 1-6C alkyl. ACTIVITY : Cytostatic; Antiallergic; Antiasthmatic; Anticoagulant; Thrombolytic; Ophthalmological; Antipsoriatic; Antiasthmatic; Antirheumatic; Antidiabetic; Antiarteriosclerotic; Anorectic; Antiparkinsonian; Antidepressant; Neuroleptic; Nootropic; Neuroprotective; Analgesic; Immunomodulator; Antiangiogenic; Vulnerary; Osteopathic. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibition of protein kinases, particularly vascular endothelial growth factor receptor 2 (KDR) and focal adhesion kinase (FAK), and insulin-like growth factor 1 receptor.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language fre
recordid cdi_epo_espacenet_FR2854159B1
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title NOUVEAUX DERIVES DE L'INDOLE, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE KDR
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A22%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BOUCHARD%20HERVE&rft.date=2008-01-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EFR2854159B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true